{
    "clinical_study": {
        "@rank": "97335", 
        "arm_group": [
            {
                "arm_group_label": "SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2", 
                "arm_group_type": "Experimental", 
                "description": "SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks."
            }, 
            {
                "arm_group_label": "SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1", 
                "arm_group_type": "Experimental", 
                "description": "SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objectives of the study are to evaluate the safety, tolerability, and efficacy\n      of two doses of CINRYZE with recombinant human hyaluronidase (rHuPH20) administered by\n      subcutaneous (SC) injection to prevent angioedema attacks."
        }, 
        "brief_title": "Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hereditary Angioedema", 
        "condition_browse": {
            "mesh_term": [
                "Angioedema", 
                "Angioedemas, Hereditary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be \u226512 years of age.\n\n          -  Have a confirmed diagnosis of Hereditary Angioedema.\n\n        Exclusion Criteria:\n\n          -  Receipt of any C1 inhibitor (C1 INH) therapy or any blood products for treatment or\n             prevention of an angioedema attack within 7 days before the first dose of study drug.\n\n          -  Be receiving prophylactic intravenous CINRYZE that exceeds 1000 units every 3 or 4\n             days (maximum weekly dose 2000 units).\n\n          -  Have received any androgen therapy (e.g., danazol, oxandrolone, stanozolol,\n             testosterone) within 7 days prior to the first dose of study drug.\n\n          -  If female, have started taking or changed the dose of any hormonal contraceptive\n             regimen or hormone replacement therapy (i.e., estrogen/progestin containing products)\n             within 3 months prior to the first dose of study drug.\n\n          -  History of allergic reaction to C1 INH products, including CINRYZE or other blood\n             products.\n\n          -  History of abnormal blood clotting.\n\n          -  Have a known allergy to hyaluronidase or any other ingredient in the study\n             formulation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756157", 
            "org_study_id": "0624-206", 
            "secondary_id": "2012-000083-24"
        }, 
        "intervention": {
            "arm_group_label": [
                "SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2", 
                "SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1"
            ], 
            "intervention_name": "CINRYZE with rHuPH20", 
            "intervention_type": "Biological", 
            "other_name": [
                "C1 esterase inhibitor (human)", 
                "Recombinant human hyaluronidase"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Complement C1 Inactivator Proteins", 
                "Complement C1 Inhibitor Protein", 
                "Complement C1", 
                "Complement C1s"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Crossover", 
            "Prevention", 
            "Hereditary Angioedema", 
            "C1 esterase inhibitor", 
            "C1 inhibitor", 
            "Subcutaneous", 
            "Recombinant human hyaluronidase"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35209"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85251"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bentonville", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72712"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Walnut Creek", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94598"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Colorado Springs", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80907"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33613"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89106"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mineola", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11501"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43235"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Oswego", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97035"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15241"
                    }, 
                    "name": "Clinical Operations Staff"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37909"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99204"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munchen", 
                        "country": "Germany"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jonkoping", 
                        "country": "Sweden"
                    }, 
                    "name": "ViroPharma Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Spain", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Randomized, Double-Blind, Multicenter, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Subcutaneous Administration of CINRYZE\u00ae (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema", 
        "overall_official": {
            "affiliation": "ViroPharma", 
            "last_name": "Jennifer Schranz, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Paul-Ehrlich-Institut", 
                "Hungary: National Institute of Pharmacy", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Sweden: Medical Products Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of angioedema attacks during each randomized therapy period", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756157"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "This score is the sum of the maximum symptom severity recorded for each angioedema attack in a treatment period.", 
            "measure": "Cumulative Attack-Severity during each randomized therapy period", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Shire", 
        "sponsors": {
            "collaborator": {
                "agency": "Halozyme Therapeutics", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Shire", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}